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This data article contains complementary ﬁgures to the research
article “Mitochondrial response to the BCKDK-deﬁciency: some
clues to understand the positive dietary response in this form of
autism” [1]. Herein we present data relative to the effect of knocking
down BCKDK gene on the real time oxygen consumption rate of
ﬁbroblasts obtained from a Maple Syrup Urine Disease (MSUD)
patient. Interference of BCKDK expression on such cells showing a
reduced branched-chain α-ketoacid dehydrogenase (BCKDHc)
activity; let us generate a scenario to study the direct effect of
BCKDK absence in an environment of high branched-chain amino
acids (BCAAs) concentrations. Data relative to the effectiveness ofvier Inc. This is an open access article under the CC BY license
/j.bbadis.2016.01.016
odríguez-Pombo).
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I. Bravo-Alonso et al. / Data in Brief 7 (2016) 755–759756the knockdown together with the potentiality of the BCKDK-
knockdown to increase the deﬁcient branched-chain α-ketoacid
dehydrogenase activity detected in MSUD patients are also shown.
& 2016 Elsevier Inc.. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations TableSubject area Biologyore speciﬁc sub-
ject areaMolecular Biology, Molecular Medicineype of data Text ﬁle, graph, ﬁgure
ow data was
acquiredqRT-PCR (LightCyclers480), XF24 Extracellular Flux analyzer (Seahorse
Bioscience, Izasa Scientiﬁc)ata format Analyzed
xperimental
factorsMSUD-patient’ ﬁbroblasts lentiviral transduced with shRNAs against BCKDK
genexperimental
featuresqRT-PCR, oxygen consumption ratio in intact cells, radiometric assayata source
locationSpainata accessibility Data is within this articleDValue of the data These data provide information to establish an adequate framework to evaluate the effect of the
BCAA deﬁciency on mitochondrial functionality in human cells.
 These data are valuable for researchers using inhibitors of BCKD kinase as therapeutic approach to
treat MSUD patients.
 These data could be relevant for Neurologist treating BCKDK-deﬁcient patients and nutritionist
involved in treatments with BCAAs.1. Data
We present data covering the characterization of BCKDK gene expression interference in ﬁbro-
blasts from a MSUD patient carrying missense changes in the gene encoding for the BCKDHE1α
subunit of the BCKDH complex, as well as the following assessment of the bioenergetics performance
of such interfered ﬁbroblasts. The evaluation of the BCKDK interference was assessed by measurement
of BCKDK mRNA by real-time PCR and protein expression through Western blot analysis. Fibroblasts’
from control and MSUD-patient interfered or not with shRNAs were included (Fig. 1A and B). The
BCKDH complex activity and mitochondrial performance upon interference were assessed by
establishment of the [1-14C]-leucine decarboxylation (see Fig. 2A) and the real-time oxygen con-
sumption rates respectively (Fig. 2B).
Fig. 2. Knockdown of BCKDK gene in MSUD ﬁbroblasts. Analysis of BCKDHc activity and bioenergetics proﬁle. (A) BCKDHc
activity was measured in MSUD ﬁbroblast's extracts (MSUD); or after lentiviral-transduction with non-target control shRNA
(sc) or shRNA1 (#1). Histogram represents the folds increases over basal. (B) Oxygen Consumption Rate -OCR- was measured as
an evaluation of mitochondrial respiratory proﬁle changes in control cells (C), non-transduced (MSUD) or lentiviral-transduced
MSUD ﬁbroblasts with non-target control (sc) or shRNA1 (sh1). Results are the mean7SD of 3–5 wells from n¼2 independent
experiments.
Fig. 1. Characterization of the knockdown of BCKDK gene in MSUD ﬁbroblasts. (A) Quantitative PCR analysis of BCKDK mRNA
relative to GAPDH in non-transduced (MSUD) or lentiviral-transduced MSUD ﬁbroblasts (MSUD shRNAs). Non-target control
shRNA (sc); shRNA1 (#1); shRNA2 (#2) were used to prove the degree of genetic expression interference. (B) Representative
Western blot of mitochondrial extracts blotted against BCKD kinase (BCKDK) to assess the BCKDK protein expression; BCKDE1α
to evaluate the presence of BCKDE1α; and Hsp60 as a loading control.
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2.1. Cell lines and culture conditions
For these studies, we used skin ﬁbroblasts from a MSUD patient carrying known mutations in the
BCKDHE1α subunit of the BCKDH complex. Control cells were the human dermal ﬁbroblasts CC2509
I. Bravo-Alonso et al. / Data in Brief 7 (2016) 755–759758obtained from Lonza (Spain). Cells were cultured with minimal essential medium (MEM) supple-
mented with 1% glutamine, 10% fetal bovine serum (FBS), and antibiotics in a humidiﬁed atmosphere
containing 5% CO2. Experiments were accomplished when cells reached 80% conﬂuence and between
the 8th and 13th passage. The institutional Ethic Committee of the Universidad Autónoma de Madrid
granted ethical approval for the use of the patient sample.
2.2. Lentiviral construct and validation
Lentiviral particles incorporating shRNAs against BCKDK (NM_00588.1) (Mission shRNA, Sigma
Aldrich, St., MO) were generated in HEK293T packaging cells by co-transfection of pLKO.1 plasmid
containing shRNA sequences, packing plasmid pCMV-dR8.74, and envelope plasmid pMD2.G
(Addgene, Cambridge, MA) using Lipofectamine and Plus reagent (Life Technologies, Carlsbad, CA).
Medium containing viral particles (non-target control shRNA -SHC002- or either of the BCKDK
shRNAs targeting different sequences of human BCKDK) were removed 48 h after transfection.
Infections of MSUD ﬁbroblasts were performed as described in [1]. ShRNA clone information: clone
TRC number: TRCN0000199200, TRCN000010196, and TRCN000010183; clone ID: NM_005881.1-
828s1c1, NM_005881.x-850s1c1, and NM_005881.x-135s1c1. http://www.sigmaaldrich.com/catalog/
genes/BCKDK?lang¼es&region¼ES#shRNA.
2.3. Real-time PCR quantiﬁcation
Success on BCKDK interference was evaluated through qRT-PCR using a LightCyclers480 instru-
ment. Total RNA was isolated using MagNaPure Compact RNA Isolation Kit and MagNaPure Compact
instrument (Roche Applied Science). RNA was retro-transcribed using the High Capacity RNA to cDNA
kit and GeneAmpPCRSystem9700 (Life Technologies). Real-time PCR was performed in a total of 10 μl,
containing 5 ng of cDNA product, 5 μl of LyghtCyclers480 SYBR Green I Master (Roche Applied Sci-
ences), and PCR primers at ﬁnal concentration of 250 nM each. GAPDH mRNA expression levels were
used as an endogenous control. The data were analyzed using LyghtCyclers480 software (Roche
Applied Sciences) correlating the initial template concentration with the cycle threshold (Ct) to obtain
the relative quantity (RQ) of RNA, deﬁned in detail in [1].
2.4. Mitochondrial isolation and western blot
Mitochondria from control and MSUD-patient ﬁbroblasts lentiviral transduced or not were iso-
lated by magnetic separation using Mitochondrial Isolation Kit human (MACSs Technology for
human, Miltenyi Biotec Inc., Germany) following manufacturer instructions. Western blot analysis of
the mitochondrial fraction was performed as described in [2]. The primary polyclonal antibodies used
were against BCKDK (ab111716; Abcam, Spain) at a concentration of 1:1000, and BCKDE1A (sc-67200;
Santa Cruz Biotechnology) at a concentration of 1:400. Anti-Hsp60 (Stressgen, Ann Arbor, MI) was
used at a concentration of 1:5000 as a loading control.
2.5. Measurement of BCKDH activity in MSUD patient ﬁbroblast after infection with BCKDK shRNA/
lentivirus
The rate of decarboxylation of [1-14C]-leucine was measured using the Wendel modiﬁed method
[3]. Cells from one 100 mm culture dish were resuspended in 200 μl of 2 mM glucose in Krebs Ringer
Phosphate buffer. The complete reaction mixture (ﬁnal volume 100 μl) for the enzyme assay con-
tained: 50 μl of cell suspension, 0.1 mM L-leucine, 10 mM glucose, 0.5 μCi [1-14C]-leucine and Krebs
Ringer Phosphate buffer. Assay proceeded during 4 h at 37 °C in a humid chamber. The activity was
expressed as pmol of CO2 released/h/mg of protein, corrected by the incorporation of [1-14C]-leucine
into proteins as a metabolic control [4]. The protein concentration was measured by the Lowry
method [5], using BSA as a standard.
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Oxygen consumption rate (OCR) was measured using the XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, Billerica, MA). 80,000 ﬁbroblasts per well were seeded in XF 24-well cell culture microplates
(Seahorse bioscience, Billerica, MA) in 250 μl of MEM 10% FBS, and incubated at 37 °C/5% CO2 for 24 h. On
the ﬁrst step of the assay, the growth medium from each well was replaced with 700 μl of MEM pre-
warmed at 37 °C. Cells were incubated at least 1 h at 37 °C to allow media temperature and pH to reach
equilibrium before the ﬁrst rate measurement. After an OCR baseline measurement, 50 μl of olygomicin,
carbonil 4-(triﬂuoromethoxy) phenylhydrazone (FCCP), rotenone and actymicin solutions were sequen-
tially added to each well to reach working concentrations of 6 μM, 50 μM, 1 μM and 1 μM respectively [6].
Once ﬁnished the OCR measurements, data were expressed as pmol of O2/min/mg protein. Protein of each
well quantiﬁed by Bradford's method (Bio-Rad) after cell lysis in 1% Triton X-100, 10% glycerol, 150 mM
NaCl, 10 mM Tris–HCl pH7.5 (RIPA buffer), were used to calibrate the oxygen consumption data. Para-
meters related to mitochondrial function could be then evaluated. Oligomycin sensitive respiration (OSR)
was determined as the difference between basal OCR and the OCR obtained after addition of oligomycin. In
this point the ATP productionwould be stopped. Injection of FCCP, an inner membrane uncoupler, will lead
to an increase in the OCR showing the maximal respiratory capacity. Finally, rotenone and antimycin A,
simultaneously added (inhibitors of complex I and III respectively) will shut down the mitochondrial
electron transfer chain (ETC), giving raise the non-mitochondrial respiration. Mitochondrial reserve
capacity could be calculated as the difference between basal respiration and maximal respiration capacity.Acknowledgments
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